drugset / Trial / NCT06953089
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Timeline
- Start
- 2025-07-18
- Primary completion
- 2030-06-30
- Completion
- 2030-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT324 | Other / unclassified | — | Intravenous |
| Subject | DB-1305 | Unknown | — | Intravenous |
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |